ArticleTherapeutic advances in musculoskeletal disease2022

Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies.

Ravi Savarirayan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.